Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Pieter S, Siebenga"'
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 981-993 (2022)
Abstract Selective inhibition of certain voltage‐gated sodium channels (Navs), such as Nav1.8, is of primary interest for pharmacological pain research and widely studied as a pharmacological target due to its contribution to repetitive firing, neu
Externí odkaz:
https://doaj.org/article/78f4b743b5cc4db5bbdbb4ef4828e4bf
Autor:
Aletta, de Wit, Pieter S, Siebenga, Ruscha W, Wijdeveld, Petra C, Koopmans, Jani A J, van Loghem
Publikováno v:
Journal of Cosmetic Dermatology. 21:5576-5583
Skin revitalizers are used for skin quality improvement purposes. Hyaluronan hybrid cooperative complexes (HCC, Profhilo®, IBSA Pharmaceuticals) are an anti-aging treatment with a large amount of pure hyaluronic acid (HA) based on stable, cooperativ
Autor:
Geert Jan Groeneveld, Guido van Amerongen, Pieter S. Siebenga, Richard P. Butt, Justin L. Hay, Aoibhinn McDonnell, Donal Gorman
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 318-324 (2020)
Clinical and Translational Science
Clinical and Translational Science
Sodium channel blockers are used for the treatment of pain, but this is limited by the lack of selectivity for different sodium channel subtypes, which can result in central nervous system and cardiovascular side effects. As such, there is special in
Autor:
Pieter S. Siebenga, Alexander L.H. Mentink, Geert Jan Groeneveld, Jan R. Buitenweg, Robert Doll, Boudewijn van den Berg
Publikováno v:
Behavior Research Methods
Behavior Research Methods, 52(4), 1617-1628. SPRINGER
Behavior research methods, 52(4), 1617-1628. Springer
Behavior Research Methods, 52(4), 1617-1628. SPRINGER
Behavior research methods, 52(4), 1617-1628. Springer
Measuring altered nociceptive processing involved in chronic pain is difficult due to a lack of objective methods. Potential methods to characterize human nociceptive processing involve measuring neurophysiological activity and psychophysical respons
Autor:
Francis M. Dijkstra, Rob G. J. A. Zuiker, Pieter S. Siebenga, Richard A. Leigh‐Pemberton, Lei Sun, Joan D. Manthis, Marieke L. de Kam, Richard Lin, Lisa L. von Moltke, David Rezendes, Joop M. A. van Gerven
Publikováno v:
British journal of clinical pharmacology. 88(6)
ALKS 7119 is a novel compound with in vitro affinity highest for the SERT, and for μ receptor, αIn 10 cohorts (n = 10 subjects each), PK, safety and PD (NeuroCart tests, measuring neurophysiologic effects [pupillometry, pharmaco-EEG (pEEG)], visuom
Publikováno v:
Clinical and Translational Science. WILEY
Clinical and Translational Science
Clinical and Translational Science
Selective inhibition of certain voltage-gated sodium channels (Na(v)s), such as Na(v)1.8, is of primary interest for pharmacological pain research and widely studied as a pharmacological target due to its contribution to repetitive firing, neuronal e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::768318174e03a1e0394a2ca61e39f2c8
https://hdl.handle.net/1887/3278291
https://hdl.handle.net/1887/3278291
Publikováno v:
Clinical and translational science. 15(4)
Selective inhibition of certain voltage-gated sodium channels (Na
Autor:
Pieter Okkerse, Guido van Amerongen, Rachel Gurrell, Pinky Dua, Richard P. Butt, Geert Jan Groeneveld, Pieter S. Siebenga, Mark Whitlock, Donal Gorman, Justin L. Hay
Publikováno v:
British Journal of Anaesthesia. 123:e194-e203
Background This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABAA) subunit selective partial positive allosteric modulator (PAM), compared with placebo and pregab
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
Objective To evaluate the analgesic potential, safety, tolerability, and pharmacokinetics of VX-150, a pro-drug of a highly selective NaV1.8 inhibitor, in healthy subjects. Design This was a randomized, double-blind, placebo-controlled, crossover stu
Autor:
Guido van Amerongen, Katrina Gore, Pinky Dua, Peter T. Loudon, Donal Gorman, Geert Jan Groeneveld, Richard P. Butt, Justin L. Hay, Pieter S. Siebenga
Publikováno v:
British Journal of Clinical Pharmacology. 84:301-309
Aim Inhibitors of nerve growth factor (NGF) reduce pain in several chronic pain indications. NGF signals through tyrosine kinase receptors of the tropomyosin-related kinase (Trk) family and the unrelated p75 receptor. PF-06273340 is a small molecule